Dr. Edwin Moses is an Operating Partner at Keensight.

Dr. Moses had a very successful career as a biopharma entrepreneur, with decades of experience in building successful businesses.

He was the former CEO of Ablynx, an innovative biopharma company acquired by Sanofi in 2018 for €3.9 billion.

Prior to Ablynx, Dr. Moses was the CEO of OAI (Oxford Asymmetry International), a clinical research organization acquired by Evotec in 2000 for $475m. During his tenure as CEO of these two companies, which he built, Dr. Moses led their IPOs on the LSE, Euronext, and NASDAQ and raised over €500m in financing. He also secured biopharma licensing transactions with a potential value exceeding €10bn.

A British national, Dr. Moses graduated from the University of Sheffield with a Bachelor’s degree and a Ph.D. in chemistry.